iShares Gold Trust vs Zimmer Biomet Holdings Inc — how do they compare? iShares Gold Trust trades at $78.86 (market cap $61.51B), while Zimmer Biomet Holdings Inc trades at $88.85 (market cap $16.95B). The key difference: iShares Gold Trust is far larger — about 3.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| IAU | ZBH | |
|---|---|---|
Market Cap | $61.51B | $16.95B |
Volume | 3,206,729 | 2,505,240 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $103.98 |
52-Week Low | $74.21 | $79.58 |
Typical Hold Time | 49 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.88, up 2.36% with a $1.82 daily gain, though technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, with support levels at $76-$77 and resistance at $78-$79. Recent news highlights gold's sensitivity to inflation data and interest rate expectations.
The outlook remains cautious due to macroeconomic headwinds and technical weakness. Investment opportunities exist if gold prices stabilize amid inflation concerns, but risks include persistent rate hikes and dollar strength. Monitor Fed policy and economic data for directional cues.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →